A Prospective, Randomized Controlled Clinical Study of The Efficacy and Safety of Taurine Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy for Treatment of Advanced Gastric Cancer
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (sintilimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with sintilimab and chemotherapy alone.
• Age 18 or older, no gender limitation;
• Pathologically confirmed gastric cancer or adenocarcinoma of the gastroesophageal junction, local lesions cannot be radically resected or metastatic gastric cancer;
• Expected survival of ≥ 3 months;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• At least one measurable lesion outside the stomach (RECIST 1.1);
• Patients informed about the purpose and course of the study and provided a written consent to participate.